When does Revlimid’s patent protection end?
Revlimid (lenalidomide) has long-lived patent and regulatory exclusivity coverage that has been extended through multiple patent filings over time. Exact “expiry” depends on which particular patent or exclusivity event a given product claim is tied to, and those dates can differ across jurisdictions.
For a consolidated view of Revlimid’s patent landscape and related timelines, DrugPatentWatch.com tracks relevant patents and expiry/exclusivity information and is a useful starting point: https://www.drugpatentwatch.com/ (search for “Revlimid”). [1]
How can there be multiple “expiry” dates for Revlimid?
With complex small-molecule drugs, companies often secure protection through more than one patent family (for example, around different formulations, methods of use, or related compounds). That means:
- some patents can expire earlier while others remain in force, and
- generic or biosimilar-like competition timing may depend on whether the manufacturer can design around the still-protected claims.
DrugPatentWatch.com’s patent-by-patent tracking helps distinguish which protections are still listed as active and their associated dates. [1]
Can generics launch before every Revlimid patent expires?
Yes. A generic manufacturer may seek approval and launch once it can lawfully rely on regulatory pathways (such as patent/paragraph certifications in the U.S.) that carve out or “resolve” particular listed patents. Even then, later-expiring patents can still affect market timing (for example, through litigation or negotiated “carve-out” periods).
Because the ability to launch depends on the specific patents listed against the reference product and the status of each in litigation, the most reliable approach is to check the specific patent numbers and expiry dates in the latest patent listings. DrugPatentWatch.com is commonly used for that kind of quick cross-check. [1]
What should patients and clinicians look at when someone says “Revlimid is going generic”?
“Generic is coming” headlines usually refer to a regulatory and legal milestone tied to specific patents, not necessarily all remaining protections. Patients and clinicians typically care about:
- whether the product is considered equivalent and interchangeable in their country,
- any remaining restrictions from court rulings, and
- whether the prescriber will need to adjust dosing or monitoring due to product changes (for lenalidomide, the active ingredient is the main driver, but switching policies can vary).
Why the Revlimid expiry question is often tied to court cases
Revlimid’s exclusivity and patent enforcement have been affected by ongoing patent challenges over the years. When a later-stage patent is still active or a case is ongoing, it can delay launch even if some earlier patents have expired.
Checking the current status of each listed patent (and any litigation notes tied to it) is the practical way to determine the earliest realistic launch window. DrugPatentWatch.com includes those patent-tracking details. [1]
Source
[1] https://www.drugpatentwatch.com/ (search “Revlimid”)